Lipid-based nanocarriers for breast cancer treatment - comprehensive review

被引:82
作者
Talluri, Siddartha Venkata [1 ]
Kuppusamy, Gowthamarajan [1 ]
Karri, Veera Venkata Satyanarayana Reddy [1 ]
Tummala, Shashank [1 ]
Madhunapantula, SubbaRao V. [2 ]
机构
[1] JSS Univ, JSS Coll Pharm, Dept Pharmaceut, Udhagamandalam 643001, Tamil Nadu, India
[2] JSS Univ, JSS Med Coll, Dept Biochem, Mysore, Karnataka, India
关键词
Breast cancer; lipid; lipid polymer hybrid nanoparticles; liposomes; nanostructured lipid carriers; solid lipid nanoparticles; POLYMER HYBRID NANOPARTICLES; DRUG-DELIVERY SYSTEM; SURGICAL ADJUVANT BREAST; IN-VITRO; MULTIDRUG-RESISTANCE; LIPOSOMAL DOXORUBICIN; THERAPEUTIC DELIVERY; ANTITUMOR-ACTIVITY; CELLULAR UPTAKE; CELLS;
D O I
10.3109/10717544.2015.1092183
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Breast cancer is the second leading cancer-related disease as the most common non-cutaneous malignancy among women. Curative options for breast cancer are limited, therapeutically substantial and associated with toxicities. Emerging nanotechnologies exhibited the possibility to treat or target breast cancer. Among the nanoparticles, various lipid nanoparticles namely, liposomes, solid lipid nanoparticles, nanostructured lipid carriers and lipid polymer hybrid nanoparticles have been developed over the years for the breast cancer therapy and evidences are documented. Concepts are confined in lab scale, which needs to be transferred to large scale to develop active targeting nanomedicine for the clinical utility. So, the present review highlights the recently published studies in the development of lipid-based nanocarriers for breast cancer treatment.
引用
收藏
页码:1291 / 1305
页数:15
相关论文
共 117 条
[1]   Neoadjuvant therapy in breast cancer: Can we define its role? [J].
Aapro, MS .
ONCOLOGIST, 2001, 6 :36-39
[2]   Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells [J].
Acevedo-Morantes, Claudia Y. ;
Acevedo-Morantes, Maria T. ;
Suleiman-Rosado, David ;
Ramirez-Vick, Jaime E. .
DRUG DELIVERY, 2013, 20 (08) :338-348
[3]   Mechanisms of phagocytosis in macrophages [J].
Aderem, A ;
Underhill, DM .
ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :593-623
[4]  
AJAY P., 2010, International Journal of Pharmacy and Pharmaceutical Sciences, V2, P30
[5]   Drug delivery of hydroxyurea to breast cancer using liposomes [J].
Alavi S.E. ;
Esfahani M.K.M. ;
Alavi F. ;
Movahedi F. ;
Akbarzadeh A. .
Indian Journal of Clinical Biochemistry, 2013, 28 (3) :299-302
[6]   Advantages of liposomal delivery systems for anthracyclines [J].
Allen, TM ;
Martin, FJ .
SEMINARS IN ONCOLOGY, 2004, 31 (06) :5-15
[7]   Efficacy of edelfosine lipid nanoparticles in breast cancer cells [J].
Angela Aznar, Maria ;
Lasa-Saracibar, Beatriz ;
Estella-Hermoso de Mendoza, Ander ;
Jose Blanco-Prieto, Maria .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 454 (02) :720-726
[8]  
[Anonymous], 2015, FACTS C CANC FACTS F
[9]   Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level [J].
Barrajon-Catalan, Enrique ;
Menendez-Gutierrez, Maria P. ;
Falco, Alberto ;
Carrato, Alfredo ;
Saceda, Miguel ;
Micol, Vicente .
CANCER LETTERS, 2010, 290 (02) :192-203
[10]   Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes [J].
Bedi, Deepa ;
Musacchio, Tiziana ;
Fagbohun, Olusegun A. ;
Gillespie, James W. ;
Deinnocentes, Patricia ;
Bird, R. Curtis ;
Bookbinder, Lonnie ;
Torchilin, Vladimir P. ;
Petrenko, Valery A. .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2011, 7 (03) :315-323